TELO
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ: TELO · HEALTHCARE · BIOTECHNOLOGY
$1.40
-3.45% today
Updated 2026-04-30
Market cap
$99.72M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.33
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | $3.94M | — | — |
| Gross profit | — | — | $-3.94M | — | — |
| Gross margin | — | — | — | — | — |
| R&D | $126492.00 | $833206.00 | $1.57M | $2.24M | $2.44M |
| SG&A | $11639.00 | $20941.00 | $600192.00 | $9.64M | $8.10M |
| Operating income | $-138131.00 | $-854147.00 | $-3.94M | $-12.24M | $-10.54M |
| Operating margin | — | — | — | — | — |
| EBITDA | $-138131.00 | $-854147.00 | $-11.43M | $48000.00 | $-10.54M |
| EBITDA margin | — | — | — | — | — |
| EBIT | $-276262.00 | $-1.71M | $-3.94M | $-12.19M | — |
| Interest expense | — | $0.00 | $1.64M | $4.34M | $0.00 |
| Income tax | $-138132.00 | $-854144.00 | $-2.30M | $-16.53M | — |
| Effective tax rate | 50.0% | 50.0% | 15.0% | 50.0% | 0.0% |
| Net income | $-138131.00 | $-854147.00 | $-13.07M | $-16.53M | $-10.41M |
| Net income growth (YoY) | — | -518.4% | -1430.4% | -26.5% | +37.0% |
| Profit margin | — | — | — | — | — |